FHFawzia Ahmad Habib

Fawzia Ahmad Habib

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fawzia Ahmad Habib has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex hormone binding globulin as a valuable biochemical marker in predicting gestational diabetes mellitus

    by Manal Abdalla Tawfeek, Eman Mohamad Alfadhli, Abdulfatah Marawan Alayoubi, Hesham Ahmad El-Beshbishy, Fawzia Ahmad Habib

    Circulating Sex hormone binding globulin (SHBG) levels are inversely associated with insulin resistance. This study was conducted to compare maternal serum SHBG level between pregnant women with normal glucose tolerance and those with gestational diabetes (GDM) and to investigate the roll of SHBG in GDM diagnosis. This was a case controlled study of 90 pregnant women, 45 women with GDM and 45 matched controls, attending obstetrics clinic at Ohud Hospital, Madina, Saudi Arabia between April 2014 and March 2015. Measurement of serum SHBG levels by Enzyme-linked immunosorbent assay (ELISA) method were done between 24 and 28 weeks of gestation. The best cut-off point of SHBG to diagnose GDM was calculated in receiver operating characteristic curve. Compared with the control group, SHBG concentrations were significantly lower in the GDM group; median 23 nmol/L (18–30) vs. 78 nmol/L (65–96), p < 0.001). The cut off value 50 nmol/L of the SHBG had 90% sensitivity and 96% specificity to diagnose GDM. Patients with GDM have lower circulating levels of SHBG than normal glucose tolerance pregnant women. Circulating concentrations of SHBG represent a potentially useful new biomarker for prediction of risk of GDM beyond the currently established clinical and demographic risk factors.


  • Compliance to iron supplementation during pregnancy

    by F. Habib, E. Habib Zein Alabdin, M. Alenazy, R. Nooh

    Iron deficiency anaemia is the most common nutritional disorder in the world. Pregnant women are at especially high risk of iron deficiency and anaemia because of significantly increased iron requirements during pregnancy. Iron supplementation during pregnancy has been recommended for women in the developing world, since usually no basic changes occur in the composition of the diet. This is a retrospective cohort study carried out in Al-Yamamah Hospital, Riyadh, Saudi Arabia, comparing the outcome of haemoglobin levels in 308 pregnant women near term with compliance to iron supplementation during the preceding pregnancy stages. Data were collected using an interview-based questionnaire for assessment of supplementation compliance and the women were divided into three categories: strictly compliant; partially compliant; and non-compliant. Haemoglobin levels were extracted from the medical records for the first antenatal visit (before 13 weeks' gestation) and compared with the level at entrance to the study at 36 weeks' gestation. Both Epi-info 2002 version 3.2 and SPSS version 10 were used for data analysis. Our results show that 49.7% used iron supplements continuously during the second and third trimesters of pregnancy; 38.3% reported partial use and 12.0% used no iron supplements. Haemoglobin levels improved significantly only among strictly compliant pregnant women, by 0.3 g/dl; decreased among partially compliant women by, 0.36 g/dl and significantly decreased among non-compliant, by –1.4 g/dl. Factors associated with non-compliance were education with a simple linear protective effect from being non-compliant. The percentage of anaemic women increased from 29.6% in the first trimester to 34% in the third trimester. Anaemia was significantly associated with non-compliance with iron supplementation, the adjusted OR was 6.19 95% CI 2.55–15.02, p < 0.0001. Strategies to improve compliance and effective iron supplementation among pregnant women should be implemented.


  • Post-treatment assessment of acuteToxoplasmainfection during pregnancy

    by F. A. Habib

    Summary Serological immune profile in cases of Toxoplasma infection is heterogeneous, and responses may be delayed or fail to be represented: this makes it an unreliable method for diagnosis and/or treatment follow-up. Therefore, the present study relied on a sensitive and specific molecular procedure (nested polymerase chain reaction, PCR), using the whole blood sample to establish the diagnosis of acute maternal toxoplasmosis in 27 pregnant women. All of them received the recommended dose of Spiramycin. Only 19 returned for follow-up visits and completed their pregnancies to full term. The achievement of the treatment regimen was evaluated according to the results of PCR amplification of T. gondii DNA at the end of the treatment course. Patients who continued to have positive PCR results were given another treatment course. After treatment with a single course of Spiramycin, 11(57.9%) patients retained T. gondii DNA in their peripheral blood and in eight (42.1%) patients, T. gondii DNA was absent by PCR: four (21.01%) patients received up to three courses of treatment.